Anne-Lise Kamper

Dr. Anne-Lise Kamper

orcid

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JOJonas Bjerring Olesen
Jonas Bjerring Olesen
GLGregory Y.H. Lip
Gregory Y.H. Lip
AKAnne-Lise Kamper
Anne-Lise Kamper
KHKristine Hommel
Kristine Hommel
LKLars Køber
Lars Køber
CTChristian Torp-Pedersen
Christian Torp-Pedersen
Both atrial fibrillation and chronic kidney disease increase the risk of stroke and systemic thromboembolism. However, these risks, and the effects of antithrombotic treatment, have not been thoroughly investigated in patients with both conditions. Using Danish national registries, we identified all patients discharged from the hospital with a diagnosis of nonvalvular atrial fibrillation between 1997 and 2008. The risk of stroke or systemic thromboembolism and bleeding associated with non–end-stage chronic kidney disease and with end-stage chronic kidney disease (i.e., disease requiring renal-replacement therapy) was estimated with the use of time-dependent Cox regression analyses. In addition, the effects of treatment with warfarin, aspirin, or both in patients with chronic kidney disease were compared with the effects in patients with no renal disease. Of 132,372 patients included in the analysis, 3587 (2.7%) had non–end-stage chronic kidney disease and 901 (0.7%) required renal-replacement therapy at the time of inclusion. As compared with patients who did not have renal disease, patients with non–end-stage chronic kidney disease had an increased risk of stroke or systemic thromboembolism (hazard ratio, 1.49; 95% confidence interval [CI], 1.38 to 1.59; P<0.001), as did those requiring renal-replacement therapy (hazard ratio, 1.83; 95% CI, 1.57 to 2.14; P<0.001); this risk was significantly decreased for both groups of patients with warfarin but not with aspirin. The risk of bleeding was also increased among patients who had non–end-stage chronic kidney disease or required renal-replacement therapy and was further increased with warfarin, aspirin, or both. Chronic kidney disease was associated with an increased risk of stroke or systemic thromboembolism and bleeding among patients with atrial fibrillation. Warfarin treatment was associated with a decreased risk of stroke or systemic thromboembolism among patients with chronic kidney disease, whereas warfarin and aspirin were associated with an increased risk of bleeding. (Funded by the Lundbeck Foundation.)

1 February 2019 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
HHHiddo J L Heerspink
Hiddo J L Heerspink
TGTom Greene
Tom Greene
HTHocine Tighiouart
Hocine Tighiouart
RGRon T Gansevoort
Ron T Gansevoort
JCJosef Coresh
Josef Coresh
WKWilliam Keane
William Keane

1 December 2014 in JACC
Verified
Journal Article
Closed access
ABAnders Nissen Bonde
Anders Nissen Bonde
GLGregory Y.H. Lip
Gregory Y.H. Lip
AKAnne-Lise Kamper
Anne-Lise Kamper
PHPeter Riis Hansen
Peter Riis Hansen
MLMorten Lamberts
Morten Lamberts
JOJonas Bjerring Olesen
Jonas Bjerring Olesen

28 May 2010 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
MFMikkel Faurschou
Mikkel Faurschou
LDLene Dreyer
Lene Dreyer
AKAnne-Lise Kamper
Anne-Lise Kamper
HSHenrik Starklint
Henrik Starklint
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen

1 October 2003 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
TJTazeen H. Jafar
Tazeen H. Jafar
CSChristopher H. Schmid
Christopher H. Schmid
PSPaul C. Stark
Paul C. Stark
RTRobert Toto
Robert Toto
Giuseppe RemuzziGiuseppe Remuzzi
Giuseppe Remuzzi
ALAndrew S. Levey
Andrew S. Levey
Background. Some studies suggest that progression of renal disease is slower in women than in men. However, other factors that are also associated with progression of renal disease have not always been taken into account. Therefore, we undertook this analysis to explore the independent association of renal disease progression with gender. Methods. We analysed a pooled database of patients with non-diabetic renal disease enrolled in 11 randomized controlled trials evaluating the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) for slowing renal disease progression. The primary end point was the combined outcome of doubling of baseline serum creatinine or onset of end-stage renal disease (ESRD). The secondary end point was the onset of ESRD alone. We performed multivariable Cox proportional hazards analysis to study the independent effect of gender on these end points after adjusting for baseline patient characteristics, and changes from baseline to follow-up systolic blood pressure (SBP) and urine protein (UP) excretion. Results. The total number of patients was 1860: 645 (35%) females and 1215 (65%) males. Mean duration of follow-up was 2.2 years. The proportions randomized to ACEI (51%), mean baseline serum creatinine (2.2 mg/dl) and mean age (52 years) were similar for both genders. Mean baseline SBP was greater in women than in men: 151 vs 147 mmHg (P < 0.001). Mean baseline UP was significantly lower in women compared with men: 1.3 vs 2.1 g/day (P < 0.001). A total of 311 (16.7%) patients developed the primary end point, and 176 (9.5%) developed the secondary end point. The unadjusted relative risk (RR) with 95% confidence interval (CI) for the primary end point in women vs men was 0.98 (0.77–1.24). It became 1.32 (1.03–1.69) after adjusting for the baseline variables and interaction between ACEIs and baseline UP, and 1.36 (1.06–1.75) after adjusting for baseline variables and changes in SBP and UP during follow-up. Similar results were found for the outcome of ESRD. Conclusions. Our findings suggest that the rate of renal disease progression may not be slower, and may even be faster in women compared with men, after adjusting for other factors associated with a faster rate of progression. We caution that most women in our database were of post-menopausal age, and thus our findings may not extend to younger women.

1 June 2007 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
DKDavid M. Kent
David M. Kent
TJTazeen H. Jafar
Tazeen H. Jafar
RHRodney A. Hayward
Rodney A. Hayward
HTHocine Tighiouart
Hocine Tighiouart
MLMarcia Landa
Marcia Landa
ALAndrew S. Levey
Andrew S. Levey
It is unclear whether patients with nondiabetic kidney disease benefit from angiotensin-converting enzyme inhibitor (ACEI) therapy when they are at low risk for disease progression or when they have low urinary protein excretion. With the use of a combined database from 11 randomized, clinical trials (n = 1860), a Cox proportional hazards model, based on known predictors of risk and the composite outcome kidney failure or creatinine doubling, was developed and used to stratify patients into equal-sized quartiles of risk. Outcome risk and treatment effect were examined across various risk strata. Use of this risk model for targeting ACEI therapy was also compared with a strategy based on urinary protein excretion alone. Control patients in the highest quartile of predicted risk had an annualized outcome rate of 28.7%, whereas control patients in the lowest quartile of predicted risk had an annualized outcome rate of 0.4%. Despite the extreme variation in risk, there was no variation in the degree of benefit of ACEI therapy (P = 0.93 for the treatment × risk interaction). Significant interaction was detected between baseline urine protein and ACEI therapy (P = 0.003). When patients were stratified according to their baseline urinary protein excretion, among the subgroup of patients with proteinuria ≥500 mg/d, significant treatment effect was seen across all patients with a measurable outcome risk, including those at relatively low risk (1.7% annualized risk for progression). However, there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d, even among higher risk patients (control outcome rate 19.7%). Patients with nondiabetic kidney disease vary considerably in their risk for disease progression, but the treatment effect of ACEI does not vary across risk strata. Patients with proteinuria <500 mg/d do not seem to benefit, even when at relatively high risk for progression.